Visterra
A company developing antibody-based biological medicines for kidney diseases and other chronic diseases. Visterra was acquired by Otsuka Pharmaceutical in 2018.
4
Funding Rounds
$153.7m
Money raised
| Name | Phone | Social networks | |
|---|---|---|---|
| Ra* Sa********** | - | - |
Funding
Funding series
Funding Series Analysis
The company Visterra has raised a total of $72.8m in funding over 4 rounds.
Key Insights:
- Visterra Series C round, October 2017: $46.7m
- Visterra Series A round: $26.1m
- Visterra Inc funding round, October 2017: $46.7m
- Visterra Series A round December 2013: $34.2m
Visterra Series C round, October 2017
$46.7m
Visterra Series A round
$26.1m
Visterra Inc funding round, October 2017
$46.7m
Visterra Series A round December 2013
$34.2m
Industries
Visterra is active in the following industries: